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Abstract
Background: A challenge in tuberculosis (TB) research is to develop a new immunological test that can help distinguish,
among subjects responsive to QuantiFERON TB Gold In tube (QFT-IT), those who are able to control Mtb replication (remote
LTBI, recent infection and past TB) from those who cannot (active TB disease). IFN-c response to the Heparin-binding-
hemagglutinin (HBHA) of Mtb has been associated with LTBI, but the cumbersome procedures of purifying the methylated
and immunological active form of the protein from Mtb or M. bovis Bacillus Calmette et Guerin (BCG) have prevented its
implementation in a diagnostic test. Therefore, the aim of the present study was to evaluate the IFN-c response to
methylated HBHA of Mtb produced in M. smegmatis (rHBHAms) in individuals at different stages of TB who scored positive
to QFT-IT.
Methodology/Principal Findings: 87 individuals at different stages of TB who scored positive to QFT-IT were selected. IFN-c
response to in vitro whole blood stimulation with rHBHAms was evaluated by short-term and long-term tests and detected
by ELISA or flow cytometry. We demonstrated that the IFN-c response to rHBHAms is mediated by CD4+ T-cells with an
effector-memory phenotype. This response, evaluated by short-term-tests, is significantly lower in active TB than in remote
LTBI (p = 0.0010) and past TB (p = 0.0152). These results were confirmed by long-term tests. The qualitative data confirmed
that IFN-c responses higher than the cut-off point identified by ROC analysis are associated with the status of non-active
disease.
Conclusions: In this study we show that the T-cell response to a recombinant and methylated HBHA of Mtb produced in M.
smegmatis is useful to discriminate between active and non-active TB disease among those responsive to QFT-IT in a whole
blood system. Further studies are needed to improve the accuracy of the assay.
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Introduction
Tuberculosis (TB) remains a major global health problem and is
one of the leading causes of morbidity and mortality due to
infection (www.who.int/tb/publications/global_report/en/) [1].
The identification of biomarkers of protection and disease
may be helpful for a better understanding of TB pathogenesis
and eventually for diagnostic purposes. A useful approach to
identify such markers could be to compare the immune
responses likely to be associated with protection in infected
non-diseased subjects, such as subjects with latent TB infection
(LTBI), with those associated in diseased patients (subjects with
active TB) [2,3].
Recently, the introduction of T-cell-based interferon (IFN)-c
release assays (IGRAs), using antigens belonging to Mycobacterium
tuberculosis (Mtb) region of difference (RD)1 [including early secreted
antigenic target (ESAT)-6 and culture filtrate protein 10 (CFP)-10],
have made a significant step towards improved LTBI diagnosis [4].
However, these tests do not discriminate between active disease,
remote LTBI, recent infection and past cured TB [5–8].
It has previously been shown that the heparin-binding
hemagglutinin (HBHA) of the MTB complex is a major latency
antigen associated to LTBI [9–11] as assessed in PBMC by
measuring IFN-c after 4 days of stimulation. It was demonstrated
that the low HBHA-induced IFN-c production in patients with
active TB [12,13] depended upon the suppressive capacity of the
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18315
T- regulatory cells in the periphery [9]. Nevertheless, no T-
regulatory specific suppression was found at the site of TB disease
and consequently a high local response to HBHA was detected
[14]. The different HBHA-specific immune response in LTBI
subjects vs. active TB patients was also observed in studies where
the humoral response against HBHA was measured [10,15–17],
confirming that HBHA is an important antigen during Mtb
infection and may be a useful biomarker to discriminate between
LTBI and active TB.
Recombinant HBHA produced in Escherichia coli is not immuno-
genic and methylation of HBHA is required for the full
immunological properties of the protein [10,11,15,18]. To
overcome the cumbersone procedures involved in the purification
of native HBHA (nHBHA) [19,20] a recombinant M. smegmatis
strain expressing the histidine-tagged recombinant HBHA protein
from Mtb (rHBHAms) was developed and used to purify a large
amount of protein [21]. The methylation pattern of rHBHAms was
similar to that observed for nHBHA (rHBHAms <16 methyl
groups vs <23 methyl groups in nHBHA [22], as assessed by mass
spectrometry analysis, Delogu G. unpublished), and this partial
methylation was shown to be sufficient to rescue the immunological
properties of HBHA as shown in humoral response studies [15–17].
Therefore, the aim of the present study was to evaluate tools
that may help to discriminate the different phases of TB among
those positive to an IGRA, i.e the QuantiFERON TB Gold In
tube (QFT-IT), due to remote LTBI, recent infection, past TB, or
active TB. In these subjects we characterized the T-cell-specific
immune response to a recombinant and methylated HBHA
produced in M. smegmatis (rHBHAms) by short and long-term
whole blood stimulation and cytometry.
Results
Characteristics of the population
We studied 24 individuals with remote LTBI, 19 with recent TB
infection, 18 with past TB and 26 with active TB. Median age,
gender, origin, BCG vaccination status and QFT-IT are reported
among the different groups (Table 1). A significant difference
among the different groups was found in terms of origin
(p,0.0001) and BCG vaccination status (p,0.0001). By ‘‘origin’’
we mean the place where the enrolled individuals were born. At
the time of enrollment they all lived in Italy where they had been
living for at least one year (median: 6 years, IQR 1–22 years).
IFN-c dose-dependent response to rHBHAms
To determine the most appropriate concentration of rHBHAms
to be used in vitro, 10 subjects with LTBI were evaluated, and the
IFN-c-specific response following in vitro short-term whole blood
stimulation with rHBHAms was assessed. As shown in Figure 1, a
significant difference was found between the IFN-c responses
when comparing rHBHAms at a concentration of 1 mg/ml to
concentrations of 25 mg/ml (p = 0.002), 10 mg/ml (p = 0.008) or
5 mg/ml (p= 0.004). No significant differences were observed for
the other pair-wise comparisons. Therefore, from hereinafter the
concentration of rHBHAms used in these in vitro assays was 5 mg/
ml.
Short-term IFN-c response to different antigens:
quantitative analysis
Response to QFT-IT. All of the enrolled subjects responded
to the mitogen (data not shown) and to QFT-IT by the selection
criteria (see materials and methods) and categorized as remote
LTBI, recent infection, past TB and active TB. No significant
differences were found among the different groups in response to
QFT-IT, except between those with a recent infection (median:
10.0 IU/ml; IQR: 1.7–10.0) and those with active TB (median:
2.25 IU/ml; IQR: 0.77–6.30) (p = 0.01) (Figure 2A).
Response to rHBHAms. IFN-c production in response to
the rHBHAms was significantly lower in those with active TB
(median: 0.2 IU/ml, IQR: 0–16.3) compared to those with remote
LTBI (median: 1.4 IU/ml, IQR: 0–28.7) (p = 0.001) and subjects
Table 1. Demographic and clinical characteristics of the subjects enrolled in the study.
Total
N (%)
87 (100.0)
Remote infection
N (%)
24 (27.6)
Recent infection
N (%)
19 (21.8)
Past TB
N (%)
18(20.7)
Active TB
N (%)
26 (29.9)
P
value
Median Age
(IQR)
39
(27–50)
48
(30.5–59)
39
(28–50)
39
(28.5–50.7)
35
(25.–44.2)
0.295
Male Gender 53 (60.9) 12 (50.0) 10 (52.6) 13(72.2) 18 (69.2) 0.325
Origin ,0.0001
Eastern Europe 33 (37.9) 3 (12.5) 4 (21.1) 11 (61.1) 15(57.7)
Western Europe 39 (44.8) 21 (87.5) 8 (42.1) 5 (27.8) 5 (19.2)
Africa 2 (2.3) - 1 (5.3) - 1 (3.8)
Asia 5 (5.7) - 1 (5.3) 1 (5.6) 3 (11.5)
South America 8 (9.2) - 5 (26.3) 1 (5.6) 2 (7.7)
BCG ,0.0001
Vaccinated 32 (36.8) 2 (8.3) 9 (47.4) 8 (44.4) 13 (50.0)
Unvaccinated 41 (47.1) 20 (83.3) 7 (36.8) 9 (50.0) 5 (19.2)
NA 14 (16.1) 2 (8.3) 3 (15.8) 1 (5.6) 8 (30.8)
QTF-IT NA
Positive 87 (100.0) 24 (100.0) 19 (100.0) 18 (100.0) 26 (100.0)
Negative - - - - -
Footnotes: TB: tuberculosis; IQR: interquartile range; BCG: Bacillus Calme`tte et Guerin; QFT-IT:QuantiFERON TB Gold In Tube; NA: not available.
doi:10.1371/journal.pone.0018315.t001
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with past TB (median: 1.1 IU/ml, IQR: 0–17.0) (p = 0.02)
(Figure 2B), and not significantly different compared to those
with a recent infection (0.7 IU/ml (IQR: 0–29.5) (p = 0.052). No
significant differences were found among the different groups
without active TB (remote LTBI, recent infection, past TB).
Response to Cytomegalovirus (CMV) lysate. As an
internal control, we evaluated the IFN-c production in response
to the recall antigen CMV. Response to CMV was analyzed in all
subjects with remote LTBI and past TB and a large portion of the
subjects from the other groups (16/19 of the recent infection
group; 25/26 of the active TB group). IFN-c response to CMV
was significantly different only between those with a recent
infection (median: 17.2 IU/ml; IQR 0.3–30.4) and those with
active TB (median: 4.5 IU/ml; IQR 0–22.9) (p = 0.002).
(Figure 2C).
All together, these data suggest that among those who scored
positive to QFT-IT, the IFN-c response to rHBHAms was more
frequently found in those able to control Mtb infection, either
naturally (remote LTBI and recent infection) or after chemother-
apy (past TB) than in those with an ongoing Mtb replication (active
disease). Noteworthy, a down regulation of the response to
rHBHAms was observed in active TB patients compared to those
with past cured TB.
In vitro short-term and long-term IFN-c responses to
rHBHAms and QFT-IT: ROC analysis and qualitative
evaluations
Because no differences were found among the subjects without
active TB for the short-term response to rHBHAms (remote LTBI,
recent infection, past TB), the data from these groups were pooled
together and indicated as results from ‘‘no active TB’’ subjects. A
significant difference was found for the response to rHBHA
between the subjects with and without active TB (p= 0.001)
(Figure 3). Therefore, based on this result, we performed a ROC
analysis to evaluate the potential use of this assay for discriminat-
ing the different stages of TB. We found significant results in the
AUC analysis (AUC, 0.72; 95% confidence interval (CI), 0.60–
0.83, p = 0.001) (Figure 4A). For scoring purposes, a cut-off value
was chosen to maximize the sum of sensitivity and specificity. The
use of a cut-off point below 0.25 IU/ml showed 50.0% sensitivity
(95% CI, 29.93%–77.89%) and 80.3% specificity (95% CI,
68.16%–89.40) to identify those with active TB. Therefore, based
on this cut-off value, we scored the results as negative and positive
and a pair-wise comparison was performed. A significantly lower
proportion of positive results was found among those with active
TB (13/26; 50%) compared to those without (12/61; 80.3%)
(p = 0.0008).
To assess the memory response, we evaluated the long-term IFN-
c production to rHBHAms in the majority of the subjects enrolled
(20/26 with active TB and 52/61 without) and a significant
difference was found between these two groups (p= 0.0003)
(Figure 3). Therefore, based on this data, a ROC analysis was
Figure 1. Concentration-dependent IFN-c response after in vitro
short-term whole blood stimulation with rHBHAms in subjects
with LTBI. Whole blood from 10 subjects with LTBI was stimulated
with or without rHBHAms at different concentrations (between 25 and
1 mg/ml). IFN-c response was evaluated after a short-term stimulation (1
day post-in vitro stimulation). A significant difference was found for the
IFN-c response obtained between 25 and 5 mg/ml and that obtained at
a concentration of 1 mg/ml.
doi:10.1371/journal.pone.0018315.g001
Figure 2. Response to rHBHAms is significantly impaired in patients with active TB. Whole blood was stimulated with or without QFT-IT
(A), rHBHAms (B) and CMV lysate (C). IFN-c response was evaluated after a short-term stimulation (1 day post-in vitro stimulation). The data are
shown after the subtraction of the results obtained in the unstimulated sample. A significant difference in terms of IFN-c release to QFT-IT (A) and
CMV lysate (C) was found between those with active TB and recent infection (p = 0.01 and p=0.002 respectively). A significant lower response to
rHBHAms (B) was found in patients with active TB compared to those with remote LTBI (p = 0.001) and past TB (p = 0.02).
doi:10.1371/journal.pone.0018315.g002
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performed and we found significant results for the AUC analysis
(AUC, 0.78; 95% confidence interval (CI), 0.64–0.91, p= 0.0002)
(Figure 4B). For scoring purposes we chose a cut-off point to
maximize the sum of sensitivity and specificity. The use of a cut-off
point below 0.75 IU/ml showed 75.0% sensitivity (95% CI,
50.90%–91.34%) and 75.0% specificity (95% CI, 61.05%–85.97)
to identify those with active TB. Therefore, based on this cut-off
point, we scored the results as negative and positive and a pair-wise
comparison was performed. A significantly lower proportion of
positive results was found among those with active TB (5/20; 25%)
compared to those without (39/52; 75.0%) (p= 0.0003).
In the same subjects, we also investigated whether the response
to QFT-IT could be useful to discriminate the different stages of
TB. No significant results for the area under the curve (AUC)
analysis were obtained (AUC, 0.62; 95% confidence interval (CI),
0.49–0.74, p= 0.07) (Figure 4C) and therefore no further
statistical analysis was performed.
All together, these data suggest that among those who scored
positive to QFT-IT, the IFN-c response to rHBHAms was more
frequently found in those able to control Mtb infection, than in
those with an ongoing Mtb replication as evaluated by both short
and long-term whole blood assays.
Memory response to rHBHAms is impaired in those with
active TB
To further assess the memory response we evaluated the long-
term IFN-c production to rHBHAms in a subgroup of the subjects
who scored negative (below 0.25 IU/ml) to this antigen on the
short-term test (11 without active disease and 11 with active TB).
As shown in Figure 5, a significant difference was found between
the IFN- c value by the short-term test (median: 0.1 IU/ml; IQR
0–0.2) and the long-term test (median: 0.6 IU/ml; IQR 0.5–5.7)
(p = 0.0003) among those without active TB. Conversely, among
those with active TB, no significant IFN-c difference was found
when the short-term test (median: 0.1 IU/ml; IQR 0–0.1) was
compared to the long-term test (median: 0.1 IU/ml; IQR 0.1–0.4)
(p = 0.4). Based on the previously established cut-off values
(Figure 4), a significantly higher proportion of memory response
was found in the subjects without active disease (5/11, 45.4%)
compared with those with active TB (0/11, 0%) (p= 0.03)
(Figure 5). All together, these data indicate that among those
with active TB, the recovery of a memory response to rHBHAms
is unlikely.
IFN-c in response to rHBHAms is mediated by CD4+
effector memory T lymphocytes
We further evaluated the phenotypic characteristics of the cells
responding to the rHBHAms in the HBHA-responders in the
short-term test. All the subjects analyzed responded to the positive
control, PMA plus IONO (data not shown). As shown in a
representative subject in Figure 6, a significant IFN-c response to
the rHBHAms was observed for CD4+ T-cells (Figure 6D) over
the negative control (Figure 6B), whereas no response was
detected for CD8+ T-cells (Figure 6C) over the negative control
(Figure 6A). To characterize this immune response, naive and
memory phenotypes were studied. Most of the CD4+ T-cells IFN-
c responding to the rHBHAms presented an effector memory
phenotype (84%) defined as CD45R0+CD62L (Figure 6 E).
Figure 3. Response to rHBHAms is significantly impaired in
patients with active TB after short- or long- term stimulation. A
significant difference was found for the IFN-c response to rHBHA
between the subjects with and without active TB (p = 0.001) evaluated
by short- or long- term stimulation.
doi:10.1371/journal.pone.0018315.g003
Figure 4. IFN-c response to rHBHAms in short- and long-term-‘‘in vitro’’ stimulation and to QFT-IT: ROC analysis. A ROC analysis for the
response to rHBHAms obtained in whole blood by short-term stimulation (A), long- term stimulation (B) and QFT-IT (C) was performed using the
active TB patients and the subjects without active TB as comparator groups.
doi:10.1371/journal.pone.0018315.g004
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All together, these data suggest that the response to rHBHAm is
mediated by CD4+ T-cells with an effector-memory phenotype.
Discussion
A major challenge in TB research is to develop a new
immunological test that can help distinguish, among subjects
responsive to QFT-IT, those who are able to control Mtb
replication (subjects with remote LTBI, recent infection and past
TB) from those who cannot (patients with active TB disease). This
discrimination would be very useful because it would allow for
targeting those needing a rapid full course therapy and thus avoid
dissemination of the infection in the community.
In this study, we show that although patients with active TB
respond to QFT-IT and to another non-Mtb recalling antigen
such as CMV, the IFN-c response to the rHBHAms was almost
absent. Moreover, no recovery of a memory response to
rHBHAms was found in these patients, different from the results
found using other Mtb-specific recalling antigens [23,24]. For the
first time to our knowledge we showed that the recombinant and
methylated HBHA of Mtb produced in M. smegmatis, which can be
easily and inexpensively produced, is immunogenic and potentially
useful to exclude active TB in a T-cell based in vitro system.
Therefore, by combining the QFT-IT score with the rHBHAms
results, we identified a potential two-step immune approach for the
identification of subjects at different stages of TB. Subjects
responding to both antigens are more likely to be able to control
Mtb replication (such as those with remote LTBI, recent infection
or past TB), while those responding only to QFT-IT are more
likely to present active TB.
In previous studies using a 4-day culture of PBMC [10], it was
shown that the IFN-c response to native HBHA, purified from M.
bovis BCG, is associated with LTBI, whereas this response is almost
lost during active TB, due to the specific suppression mediated by
the regulatory T-cells [9]. Therefore the assay based on IFN-c in
response to HBHA has been proposed either to discriminate LTBI
subjects from patients with active TB or to increase the sensitivity
and specificity of RD1-based IGRAs [13]. However, since
orthologs of HBHA have been identified in other mycobacterial
species, including environmental mycobacteria [20] and BCG,
and consequently positive IFN-c responses to HBHA have been
found in BCG-vaccinated subjects [12], the specificity of an
HBHA-based assay was questioned.
In the present study, we implemented a potential diagnostic
algorithm that relies on the well-documented ability of the QFT-
IT to identify Mtb infection [25]. Therefore among those positive
to QFT-IT, we used HBHA as a tool to distinguish the different
stages of TB. The results indicate that the accuracy of the long-
term test, that mostly measures a memory response [23], was
greater compared to that reported for the short-term test that
measures mostly the effector response, as shown here by flow
cytometry data. Based on these results, the long-term whole blood
assay may be more accurate for identifying those with active
disease (positive response to QFT-IT, negative response to
rHBHAms). Moreover, we showed that BCG vaccination did
not have any impact on the IFN-c response to HBHA. In fact
individuals with active TB and past TB, although presenting a
similar proportion of BCG-vaccinated individuals (table 1),
showed a significantly different IFN-c response to HBHA
(Figure 2B).
The use of HBHA as a biomarker in TB could be crucial, for
instance in patients with active TB disease, to predict durable
(non-relapsing) treatment success or in subjects with LTBI to assess
reactivation risk [26]. This could be of paramount importance in
Figure 5. Memory responses to rHBHAms. Memory response (long-term stimulation) to rHBHAms was evaluated in the subjects who scored
negative on the short- test. A significant difference was found between the IFN-c value obtained in the short-term stimulation compared to the long-
term stimulation among those without active TB (p = 0.0003). Differently, no significant difference was found between the short- and long- term
stimulation among those with active TB (p = 0.4). The data are shown after the subtraction of the results obtained in the unstimulated samples.
Dotted lines indicate the cut-off obtained for the short- and long-term tests.
doi:10.1371/journal.pone.0018315.g005
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populations that are at a higher risk of developing active TB, such
as HIV-positive subjects, in communities with a high TB
prevalence [27] , subjects with rheumatoid arthritis [5], or patients
for whom diagnosis of active TB and monitoring or treatment may
be difficult, such as pediatric patients [26]. Further studies
specifically addressing these questions will provide a clearer
picture on the usefulness of the QFT-IT/rHBHAms combination
assay to identify different TB status.
A major finding of this study was also that the T-cell response
against HBHA is quantitatively and qualitatively different
depending on the stages of infection. This is remarkable since
we could measure a quantitative difference in the QFT-IT
response between the group of the recently infected subjects and
the active TB patients, but not in the other groups investigated.
Similar results were obtained using CMV lysate, a non-Mtb
specific antigen, suggesting that the difference obtained by
analyzing the QFT-IT data was not Mtb-specific. Conversely,
the secretion of IFN-c induced by rHBHAms was significantly
lower in the group of patients with active TB and was rescued
following successful anti-TB therapy, as shown by the results
obtained in the group of subjects with past cured TB. This switch
in the T-cell response specifically directed against HBHA
epitopes was observed by assays that measure both effector
and memory response (1- day and 7- day tests) [23], indicating
that the emergence of TB disease correlates with a significant
change in the HBHA-specific immune response. It would be of
interest to understand whether the modulation of HBHA
expression by the bacilli during infection can induce this change
in the host response and promote disease progression, as studies
in animal models suggest [28] or whether the switch that we
observed was an effect independent from the HBHA role in
pathogenesis.
Figure 6. CD4+ effector memory T lymphocytes produce IFN-c in response to rHBHAms. The phenotypic characteristics of the cells
responding to the rHBHAms in the HBHA-responders were evaluated. As shown in a representative subject, a significant IFN-c response to the
rHBHAms was observed for CD4+ T-cells (D) over the negative control (B), whereas no response was detected for CD8+ T-cells (C) over the negative
control (A). To characterize this immune response, naive and memory phenotypes were studied. Most of the CD4+ T-cells IFN-c responding to the
rHBHAms presented an effector memory phenotype (84%) defined as CD45R0+CD62L (E).
doi:10.1371/journal.pone.0018315.g006
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The classical dichotomy between active TB and LTBI is being
reconsidered in favor of a continuous and dynamic spectrum of
conditions extending from infection to disease [2,27]. This
spectrum of TB results from the interaction between the host
immune response and the pathogen and can be maintained in a
dynamic and variable equilibrium for decades. Moreover, in the
same TB patients, diverse lesions ranging from sterility to multi-
bacillary disease have been observed, suggesting that the entire
spectrum of TB can coexist in the same individual [2,27,29]. In
this scenario, the observation that the host immune response
against a single antigen (HBHA) is dependent on the specific TB
status is of the utmost importance [3]. The results of this study
highlight the potential usefulness of rHBHAms as a biomarker for
TB in association with the RD1-based IGRAs. rHBHAms can be
obtained through a simplified protocol, therefore, if these data are
confirmed in larger , blinded studies, their implementation in the
current clinical laboratory settings can become feasible and
economic. In conclusion, for the first time to our knowledge, we
showed that the T-cell based response to a recombinant and
methylated HBHA of Mtb produced in M. smegmatis in a whole
blood system is immunogenic and potentially useful to discrimi-
nate active from non-active disease. Further studies are needed to
improve the accuracy of the assay and to prove its reproducibility.
Materials and Methods
Study population
The study was approved by the Ethical Committee of the
National Institute of Infectious diseases L. Spallanzani (‘‘Parere
18/2002’’, INMI) and all enrolled individuals provided written
informed consent. Upon enrollment, demographic and epid-
emiological information was collected through a structured
questionnaire.
The following individuals were enrolled: 1) ‘‘remote LTBI’’,
individuals who scored positive to TST and QFT-IT and reported
household or equivalent close contact with smear-positive
pulmonary TB patients in the 3 years before enrolment; 2)
‘‘recent infection’’, individuals who reported household or
equivalent close contact with smear-positive pulmonary TB
patients in the previous 3 months, scored positive to TST and
QFT-IT but who had not yet started a specific prophylaxis;
3)‘‘active TB’’, individuals diagnosed either by a positive culture
for Mtb from sputa or with a positive Mtb-specific RNA
amplification (MTD Test, Gen-probe, San Diego, USA) from
biopsy specimens and/or biological fluids) who started specific
treatment within a month and scored positive to QFT-IT; 4) ‘‘past
TB’’, individuals with documented culture-positive pulmonary TB
who successfully completed anti-TB treatment (culture-negative
upon treatment completion), who were evaluated from 6 months
up to 2 years after treatment and had scored positive to QFT-IT at
the time of the study.
Individuals who tested positive to a human immunodeficiency
virus (HIV) antibody test or were on immunosuppressive drugs
were not included in the study. Subjects with underlying immune-
mediated disease were also excluded.
Purification of the methylated HBHA
Recombinant methylated HBHA was purified from M. smegmatis
pMV3-38 as previously described [21]. Briefly, the M. smegmatis
pMV3-38, expressing the histidine-tagged, full length HBHA
under the control of the hbhA promoter, was grown in Sauton
media for three days until late log phase was reached. Cells were
harvested by centrifugation, lysed by sonication and the cell lysate
was subjected to Nickel chromatography (X-Press, Invitrogen).
The fractions containing the purified protein were dialysed in
phosphate-buffered saline pH 7.0 (PBS) and concentrated using
Amicon Centricon Centrifugal filter devices (Millipore, Beverly,
MA USA). Batches of purified protein of 1 mg/ml were stored at
280uC until used.
TST
TST was administered by the Mantoux procedure using 5 IU of
purified protein derivative (Chiron, Siena, Italy). Results were read
after 72 hrs. Indurations of at least 5 mm or$10 mm were scored
as positive for close contacts or for the other conditions,
respectively [30] .
Whole blood enzyme linked immunosorbent assays with
rHBHAms
1-day (short-term) response. 0.5 ml per well of heparinised
whole blood was seeded in a 48-well plate (Corning Costar,
Corning Incorporated, New York, NY, USA) and treated with
phytohaemagglutinin (PHA) at 5 mg/ml (Sigma, St Louis, MO,
USA), rHBHAms at 5 mg/ml unless differently indicated, and
human CMV lysate antigen from the strain AD 169, at 5 mg/ml
(Advanced Biotechnologies Inc. Columbia, MD). Samples were
then incubated for 20–24 hrs; supernatant was then harvested and
stored at 220uC until tested.
7-day (long-term) response. We used the previously
described methodology [23]. Briefly, on the day of blood
collection, an aliquot of heparinised blood was diluted 5-fold
using RPMI 1640 supplemented with penicillin, streptomycin and
2 mM L-glutamine (the last four products are from Euroclone Ltd,
United Kingdom), plated into 48-well plates (Corning Costar) and
stimulated as described above. The day-7 diluted supernatant was
harvested following incubation at 37uC and stored at 220uC until
tested.
The persons performing the assays were blinded to the clinical
status of the samples being tested.
IFN-c determination
IFN-c from day-1 and day-7 supernatant was evaluated by a
commercial ELISA (CMI, Cellestis Limited, Carnegie, Victoria,
Australia) and data were presented as IU/ml after subtraction of
the appropriate control.
Commercially available IGRA
QuantiFERON TB-Gold In tube (QFT-IT) (Cellestis Limited)
was performed and its results were scored as indicated by the
manufacturer (the cut-off value for a positive test was 0.35 IU/ml).
Phenotypic and functional FACS analysis
The phenotypic and functional analysis of peripheral whole
blood cells was performed by flow cytometry after overnight
culture in complete medium in the presence or absence of the
following stimuli: phorbol-12-myristate-13-acetate (PMA) at 3 nM
(SERVA Electrophoresis GmbH, Heidelberg, Germany) plus
ionomycin (IONO) at 1,5 mM (SERVA) used as positive controls
and rHBHAms at 5 mg/ml. Expression of different markers was
assessed by staining with appropriate combinations of monoclonal
antibodies (MoAb) directly conjugated to fluorochromes: allophy-
cocyanin (APC)-H7-conjugated anti-CD4; peridinin chlorophyll-
protein (PerCP)-Cy5.5-conjugated anti-CD8; phycoerythrin (PE)-
Cy7-conjugated anti-CD45RO, allophycocyanin (APC)-conjugat-
ed anti-CD62L (all from Becton Dickinson (BD) Biosciences, San
Jose, USA). To detect intracellular expression of cytokines, 50 mg/
ml of Brefeldin A (SERVA) was used, as previously described.
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Briefly, production of IFN-c was assessed by staining with
appropriate combinations of MoAb conjugated directly to
fluorochromes [fluorescein isothiocyanate (FITC)-conjugated anti-
IFN-c 2 (BD)]. The cells were stimulated in vitro for 1 day with
anti-CD3 and anti-CD28 antibodies of 2 mg/ml each (BD). Data
acquisition and analysis were performed on an FACS CantoII flow
cytometer (BD) using FACSDiva software (version 6.1.2; BD). For
all staining procedures, an isotype-matched negative control was
processed in parallel.
Statistical analysis
The main outcome of the study was the evaluation of IFN-c
production in response to antigenic stimulation, expressed as
continuous (IU/ml) or dichotomous (positive/negative) measures.
The median and IQR of IFN-c production were calculated; the
Mann-Whitney U test was used to compare medians for pair-wise
comparisons; the Kruskal-Wallis test was used to compare medians
among the different groups. The cut-off value for scoring purposes
was defined by a receiver-operator characteristic analysis (ROC);
the chi square was used for dichotomous measures. SPSS v 14 for
Windows (SPSS Italia Srl, Bologna, Italy) and Prism 4 software
(Graphpad Software 4.0, San Diego, CA, USA) were used in the
analysis. Differences were considered significant at p values#0.05.
In this study we used the term sensitivity for the detection of the
‘‘condition having active TB’’ when we measured the proportion
of actual individuals with active disease who were correctly
identified as such. We used the term ‘‘specificity’’ for the detection
of the ‘‘condition not having active TB’’ when we measured the
proportion of those without active TB who were correctly
identified as such.
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